Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
315 Leser
Artikel bewerten:
(2)

King Faisal Specialist Hospital & Research Centre: A Life Rewritten: KFSHRC Treats Rare Disease After 22 Years of Specialized Care

News size

RIYADH, Saudi Arabia, July 09, 2025 (GLOBE NEWSWIRE) -- In a rare example of a lifelong bond between a patient and a healthcare institution, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has continued to support a patient since infancy, providing 22 years of continuous care for a rare genetic blood clotting disorder, ultimately culminating in a liver transplant-the first of its kind globally for this particular condition.

When the early signs of illness appeared during the patient's first months of life, KFSHRC teams raced against time to stabilize her condition. She was diagnosed with a congenital deficiency in plasminogen, a protein essential for dissolving blood clots, resulting in fibrous deposits that posed serious threats to her tissues and organs.

The complexity of her case posed both medical and quality-of-life challenges, requiring a comprehensive, multidisciplinary care system. This extended beyond medical treatment to include all facets of life-supporting care. Teams from nursing, nutrition, and information technology joined hematology and transplant specialists to ensure the young girl's well-being.

In a reflection on the early days, the patient's father said: "My daughter suffered from the moment she was born. She cried constantly and couldn't nurse. We lived in continuous worry with no clear answers until God opened a door of hope. Today, thanks to God first, and then to the remarkable healthcare capabilities provided by the Government of the Custodian of the Two Holy Mosques and His Royal Highness the Crown Prince, may God preserve them, we witness our daughter's recovery from this rare disease after two decades of struggle."

Throughout the years of treatment, the patient relied on regular intravenous doses of plasminogen, along with eye drops to reduce the disease's effect on her vision. The annual cost of treatment exceeded 6 million SAR, fully covered by the Saudi government. This reflects the Kingdom's profound commitment to human health and its investment in quality of life even in the most complex medical cases.

Dr. Hazzaa Al-Zahrani, Director of Adult Hematology and Stem Cell Transplant Division at KFSHRC Riyadh and the supervising physician, explained that managing the case required a precise and long-term approach to prevent complications and ensure stability. The decision to proceed with a liver transplant came after careful consideration as an extraordinary therapeutic option for an exceptionally rare case. The success of the procedure marked a turning point in her medical journey and a beacon of hope for patients facing similar conditions worldwide.

This approach is deeply rooted in the vision of King Faisal Specialist Hospital & Research Centre, which places the patient at the core of every practice and is committed to delivering integrated care where scientific expertise meets human compassion, in line with its mission to serve society at the highest standards.

For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/850971e1-ae0f-4702-9148-d6a28a85bf3e


© 2025 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.